Amphastar Pharmaceuticals Inc

1. 1

   Election of Directors

   ManagementBoard: FOR

   Elect three Class I directors (David Gaugh, William J. Peters and Jacob Liawatidewi) to serve three-year terms until the 2029 annual meeting and until their successors are elected and qualified.

2. 2

   Ratification of Appointment of Independent Registered Public Accounting Firm

   ManagementBoard: FOR

   Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

3. 3

   Advisory Vote on the Compensation of Our Named Executive Officers (Say-on-Pay

   ManagementBoard: FOR

   Non-binding, advisory vote to approve the compensation paid to the Company's named executive officers as disclosed in the proxy statement, including the CD&A and compensation tables.

   More detail

   This advisory Say-on-Pay proposal asks shareholders to endorse the overall compensation of the named executive officers as disclosed in the proxy materials, which the Company seeks under the Dodd-Frank framework to obtain investor feedback on pay practices. Management is pursuing approval as a non-binding affirmation that its mix of base salary, short-term incentives (performance-based bonuses tied to sales, stock price, filings/approvals and corporate goals), and long-term equity (50/50 mix of options and RSUs with multi-year vesting) is appropriate and aligned with stockholder interests. The compensation committee uses peer group benchmarking and an independent consultant to set pay levels; in 2025 the committee increased targeted equity values modestly to move toward the 75th percentile and retained performance metrics tied to revenue, filings and approvals, adjusted net income and stock performance. The Board emphasizes that although the vote is non-binding, it has historically valued stockholder input (a ~95% support for the 2025 Say-on-Pay) and will consider the outcome in future compensation decisions. Management frames the program as balancing retention (RSUs), upside alignment (options), and annual accountability (PBBs and discretionary bonuses) while maintaining clawback and stock ownership guidelines. A vote FOR signals shareholder support for the Company’s current pay philosophy and reduces the likelihood of near-term program changes; a vote AGAINST could prompt outreach and potential design changes, especially around pay quantum or performance metrics. Given the program’s reliance on both near-term operational metrics and long-term equity incentives, sophisticated investors should weigh the relative stringency of the PBB thresholds, vesting schedules, and peer benchmarking when assessing whether pay is sufficiently performance‑driven. The compensation committee’s emphasis on responsiveness and past strong shareholder support suggests management expects a favorable outcome but remains accountable to investors through ongoing disclosure and engagement.

4. 4

   Advisory Vote on the Frequency of Future Stockholder Advisory Votes on Named Executive Officer Compensation

   ManagementBoard: FOR

   Non-binding, advisory vote to indicate whether shareholders prefer future Say-on-Pay advisory votes every one, two, or three years (or abstain); the Board recommends one year.

   More detail

   This advisory frequency proposal asks shareholders to indicate (one, two, or three years) how often the Company should hold a non-binding Say-on-Pay vote. Management favors an annual vote to ensure frequent stockholder feedback that the compensation committee can use when setting pay for the following fiscal year; the Board points to a prior 2020 majority preference for annual votes as supporting context. Structurally, an annual cadence increases investor engagement and timeliness of feedback but imposes more frequent administrative and disclosure cycles; multi-year cadences (two- or three-year) reduce administrative frequency and can be defended where compensation arrangements are long‑term, but they reduce the immediacy of shareholder input. Because the vote is non-binding, the outcome serves as a signal rather than a mandate; however, a clear shareholder preference for a less frequent cadence could relieve some pressure on the compensation committee to solicit and react to annual input. The Board’s recommendation of one year suggests it values iterative investor dialogue and anticipates using annual results to inform near-term pay design and target-setting, particularly given the Company’s use of annual PBB metrics. For investors assessing governance quality, the choice balances responsiveness against efficiency; activists may prefer annual votes for accountability, while index or long-term holders may rationally support multi-year votes if pay is already linked to multi-year outcomes. The compensation committee’s openness to consider stockholder feedback and historical precedent of an annual preference indicate management will treat the outcome seriously despite its advisory nature. Ultimately, the result will guide how often shareholders formally express views on CEO/NEO pay and may influence the cadence of Company-stockholder engagement on compensation topics.

Upcoming shareholder meetings at Amphastar Pharmaceuticals Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Amphastar Pharmaceuticals Inc 2026 annual meeting?

Amphastar Pharmaceuticals Inc (AMPH) holds its 2026 annual shareholder meeting on Monday, June 1, 2026.

What is the record date for the Amphastar Pharmaceuticals Inc 2026 meeting?

The record date for the Amphastar Pharmaceuticals Inc 2026 meeting is Monday, April 6, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Amphastar Pharmaceuticals Inc's 2026 meeting?

The board is presenting 3 director nominees at the Amphastar Pharmaceuticals Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Amphastar Pharmaceuticals Inc 2026 meeting?

Shareholders will vote on 4 proposals at the Amphastar Pharmaceuticals Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.